Navigation Links
Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
Date:11/17/2010

RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS. The data from study SB-509-801 demonstrated that the drug was well-tolerated in subjects with ALS and that 40% of SB-509 treated subjects had delayed deterioration of toe and ankle muscle strength as measured by manual muscle testing (MMT) compared to 23% of baseline-matched historic controls.  In addition, positive improvements in electrophysiological measures of motor nerves were observed in a subset of treated subjects.  The data were presented at the Society for Neuroscience Annual Meeting which is being held in San Diego.  

"These data are consistent with the delay in muscle deterioration that we have observed in both preclinical models of ALS as well as in clinical studies of this drug in subjects with diabetic neuropathy, a condition that is also characterized by degeneration and deterioration of nerve function," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our primary aim in this trial was to assess safety and tolerability of treatment with SB-509 in this vulnerable patient population and to conduct a signal-seeking study in which we assessed the effect of treatment on several clinical measures of function in ALS.  As this was an early-stage trial, for safety reasons we treated subjects twice over a 90 day period, although our positive preclinical animal data were achieved with a more frequent dosing schedule.  With that said, the delayed deterioration in muscle strength in the ankle and toe are very encouraging and may reflect the importa
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
3. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
4. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
7. Sangamo Announces Closing of Common Stock Offering
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/rt3mhz/deciphering ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing Demands ... It has been publicly recognized that global ... series of challenges in the recent years. The ... in small molecule product manufacturing; increasingly challenging process ...
(Date:7/7/2015)... 7, 2015   Decision Resources Group ... dialysis patient management in the U.S. versus the ... U.S. and EU5 nephrologists from approximately 1,870 dialysis ... the most commonly used renal medications in dialysis ... considerably between the two regions.      Other ...
(Date:7/7/2015)... BANGALORE , July 7, 2015 ... innovative clinical trial data management solutions, has been featured ... publication named " EDC and eCOA / ePRO Market ... is one of the leading providers of research and ... 22 EDC and eCOA / ePRO tools in the ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Inc. (Nasdaq: STRM ) today announced financial ... ended January 31, 2011. Highlights for the ... purchase contracts for add-on licenses with existing clients totaling ... recognized during the quarter; Company completed and ...
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
Cached Medicine Technology:Streamline Health® Solutions Reports Q4 Results 2Streamline Health® Solutions Reports Q4 Results 3Streamline Health® Solutions Reports Q4 Results 4Streamline Health® Solutions Reports Q4 Results 5Streamline Health® Solutions Reports Q4 Results 6Streamline Health® Solutions Reports Q4 Results 7Streamline Health® Solutions Reports Q4 Results 8Streamline Health® Solutions Reports Q4 Results 9Streamline Health® Solutions Reports Q4 Results 10Streamline Health® Solutions Reports Q4 Results 11Streamline Health® Solutions Reports Q4 Results 12Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:7/7/2015)... ... 2015 , ... Celestix Networks, the leading provider of secure ... virtual appliances. These virtual platforms expand the existing physical appliances under the ... simplify the on-premises deployment of unified remote access and single sign-on (SSO). The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today ... to access its antibody combination therapy (ACT) technology platform. The platform has ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency ... its patient community using its IDF ePHR, an electronic personal health record powered ... (PI) to easily track their health information, including symptoms, diagnoses, medications, infusions and ...
(Date:7/7/2015)... ... July 07, 2015 , ... On June 22nd-26th, 2015, the ... the National Baptist Convention 110th Annual Session of the National Baptist Congress of ... of churches and their congregations, medical professionals and health-related organizations, this week long ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri , ... treatments. A professional teeth whitening is one of the fastest, easiest ways to brighten ... they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, patients ...
Breaking Medicine News(10 mins):Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3
... estimates savings of more than $60 million over 11 years ... of air bags and seat belts significantly reduces injuries to ... and also lowers in-hospital death rates, injury severity and hospital-acquired ... It also suggests that optimal use of air bags could ...
... Ill. Recent studies have linked sleep loss ... obesity, diabetes, high blood pressure and stroke. The ... discussed by more than 5,000 scientists and sleep specialists ... Associated Professional Sleep Societies convenes at the Baltimore Convention ...
... The Joint Annual Meeting of the American Society of Plant ... y Biologia Molecular de Plantas will be held June 2225, ... , A major theme of this year,s annual meeting ... in the America,s. Presentations will also focus on ...
... clinicians identify best treatment ... risk of heart disease, BIRMINGHAM, Ala., May 28 ... its VAP,Cholesterol Test in booth No. 4202 at the American ... June 6 -,10, 2008, at the Moscone Convention Center in ...
... China, May 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... or ,the Company,), a,manufacturer, marketer and distributor of ... that it has engaged MSPC,Certified Public Accountants and ... May 21, 2008. The Company terminated its,contract with ...
... to complete electronic records, CINCINNATI and MONTREAL, ... STRM ) and Emergis Inc., a TELUS company,today ... and,workflow solution at the eight hospitals representing the ... McGill University,Health Centre (MUHC). The module is integrated ...
Cached Medicine News:Health News:Air Bags-Seat Belts Cut Injuries, Deaths, Costs 2Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 2Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 3Health News:ASPB engages Latin America colleagues at Annual Meeting in Merida, Mexico June 22-25 2Health News:ASPB engages Latin America colleagues at Annual Meeting in Merida, Mexico June 22-25 3Health News:Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 2Health News:China Sky One Medical, Inc. Engages Moore Stephens as New Independent Auditor 2Health News:China Sky One Medical, Inc. Engages Moore Stephens as New Independent Auditor 3Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 2Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 3Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 4Health News:Streamline Health's Document Management Solution Integrated into Oacis, Allowing Clinicians to Access Patients' Information - Either Scanned or Electronic 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: